Alexandra Gerlach, Content Producer

Approximately 15% of patients with polycythemia vera will progress to myelofibrosis.

In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.

Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.

Bisphenol A (BPA) is a chemical compound that is linked to various adverse health effects.

Liz Vogel, CPhT-Adv, CSPT, discusses the procedures and best practices for safe compounding of hazardous and non-hazardous drugs.

Evolving understanding of attention deficit hyperactivity disorder (ADHD) underscores the need for inclusive research and support, especially for women.

Apalutamide is a hormone therapy indicated for men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Pharmacy Times will be at the NCODA Fall Summit in Orlando from October 23 to October 25, 2024.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

Zolbetuximab is the first approved CLDN18.2-targeted treatment for gastric and gastroesophageal junction adenocarcinoma.

The tool can detect cell changes and mutations that drive resistance and relapse.

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

Cardiovascular diseases have a significant impact on brain health and function.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.

Survodutide is a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist that activates the glucagon and GLP-1 receptors to better control metabolic function.

Treosulfan showed superior benefits to busulfan as a conditioning regimen before allogenic hematopoietic stem cell transplantation (allo-HSCT).

Zodasiran is an RNA interference therapy targeting the ANGPTL3 loss-of-function mutation.

Pelabresib, a BET inhibitor, demonstrated meaningful reductions in spleen inflammation and anemia.

Research showed that children born via assisted reproductive technology were 36% more likely to develop heart defects.

High cholesterol levels are known risk factors for atherosclerotic cardiovascular disease.

Cholesin, a hormone found in the gut, may enhance the cholesterol-lowering capabilities of statins.

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

The findings may offer patients treatment options beyond symptom palliation.